



Phoenix Eagle News Release - 1 December 2009

Phoenix Eagle has achieved a significant milestone, with the Human Research Ethics Committee at the Austin Hospital approving a clinical trial of OPAL A on venous and pressure ulcers of patients attending the Wound Clinic at the Heidelberg Repatriation Hospital.

The trial will commence on 15 January 2010 and is expected to be completed in 18 months. The actual date of completion will depend on the recruitment rate and the percentage of recruits who pass into the trial proper from an initial screening stage lasting 4 weeks.

During the screening stage each patient will receive better treatment than current best practice. Patients whose ulcers reduce in size by 25% or more will be excluded from the trial proper. The second stage (trial proper) will last 12 weeks or up until closure of the ulcer, whichever comes first. The trial proper has been designed to investigate the safety and effectiveness of OPALA in the treatment of **hard-to-heal** venous and pressure ulcers.